F.I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA.
Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Ocul Immunol Inflamm. 2022 Jan 2;30(1):198-202. doi: 10.1080/09273948.2020.1774906. Epub 2020 Aug 11.
Sub-analysis of the FAST Trial comparing change in CD4 (∆CD4) from baseline through 12 months in uveitis patients treated with mycophenolate mofetil (MMF) and methotrexate (MTX).
Patients were randomly allocated to 1.5 g twice daily MMF or 25 mg weekly MTX. Individuals with CD4 counts at baseline, 6 months (or treatment failure prior), and 12 months (or treatment failure between 6 and 12 months) were included. The association between treatment and ∆CD4 (cells/μL) was analyzed using multivariable linear regression.
There was no significant difference in ∆CD4 between MMF and MTX at 6 months (-31.7 cells/μL for MMF compared to MTX; 95% CI: -358.2 to 294.8, = .85) and 12 months (-78.3 cells/μL for MMF compared to MTX; 95% CI: -468.0 to 311.3; = .69).
There was no significant difference in ∆CD4 between MMF and MTX from baseline to 12 months, suggesting that MMF does not confer additional risk of CD4 lymphopenia in uveitic patients.ClinicalTrials.gov Identifier: NCT01829295.
对 FAST 试验的亚组分析比较了接受吗替麦考酚酯（MMF）和甲氨蝶呤（MTX）治疗的葡萄膜炎患者从基线到 12 个月时 CD4 变化（∆CD4）。
患者被随机分配到 1.5g 每日两次 MMF 或 25mg 每周 MTX。纳入了基线、6 个月（或治疗失败前）和 12 个月（或 6 至 12 个月之间治疗失败）时 CD4 计数的个体。使用多变量线性回归分析治疗与 ∆CD4（细胞/μL）之间的关联。
在 6 个月时，MMF 和 MTX 之间的 ∆CD4 没有显著差异（MMF 与 MTX 相比为-31.7 细胞/μL；95%CI：-358.2 至 294.8， = 0.85）和 12 个月时（MMF 与 MTX 相比为-78.3 细胞/μL；95%CI：-468.0 至 311.3； = 0.69）。
从基线到 12 个月，MMF 和 MTX 之间的 ∆CD4 没有显著差异，这表明 MMF 不会给葡萄膜炎患者带来 CD4 淋巴细胞减少的额外风险。
ClinicalTrials.gov 标识符：NCT01829295。
